Sylexis Limited is managed by Dr Gillian Pritchard, an experienced pharmaceutical physician with expertise in early and late phase product development in Europe and the US, to ICH-GCP standards, across several therapeutic areas, e.g. clinical pharmacology, diabetes & cardiovascular medicine.

Prior to establishing Sylexis, Gillian was Medical Director of a pharmaceutical and medical devices consultancy. Some of the projects that Gillian worked on in this role included:

• Market assessments for a biomedical research park, a drug discovery facility and several new medical treatments.
• Development planning for new medical treatments.
• Developing and delivering an ICH-GCP training course.
• Providing training in pharmaceutical development.
• Developing in-house SOPs and document templates.
• Conducting a literature review to support CE marking of a medical device.

Some of Gillian’s previous roles include:

• Associate Director in Clinical Development of a global pharmaceutical company. This position involved the design, planning and conduct of an international phase III programme in type 2 diabetes to evaluate a hypoglycaemic agent administered by a medical device.
• Deputy Medical Director at a phase I clinical research unit.
• Honorary clinician at the Hypertension Clinic and Diabetes Centre of a teaching hospital.

Gillian is a Member of the Faculty of Pharmaceutical Medicine (MFPM) and a Member of the Royal College of Physicians in the UK (MRCP). She has been awarded an MBA from the University of Dundee and a Master of Science (Clinical Pharmacology) from the University of Aberdeen.

Gillian is also a member of BioDundee and of the European Medical Writers Association.